Qualifications

2018: Fellow of the Higher Education Academy (FHEA)

2011: PhD Molecular Biology of Cancer, Newcastle University

2006: BSc Biomedical Sciences, Newcastle University (First class)

Awards

Pathological Society Meeting Bursary. March 2018.

NanoString RNA:Protein competition awardee. May 2016.

EMEA Affymetrix Tumour Profiling competition awardee. April 2016.

British Council Researcher Links Scholarship - Extracellular Vesicles Workshop, Russia. Feb 2015.

Life Technologies Ion Torrent™ Transcriptome Profiling competition awardee. Jan 2015.

NanoString PanCancer Panel Driver Genes and Cancer Pathways competition awardee. April 2014.

NEPAC Travel Scholarship - American Society of Haematology 56^th Annual Meeting. Dec 2014.

BACR non-student Travel Award - 12th International Conference on Malignant Lymphomas. June 2013.

First Poster Prize, Euroscicon Meeting - Biomarker Discovery: Driving Technologies. Feb 2013.

BSH Travel Scholarship - ESH International Conference on Lymphomas. Oct 2012.

ESH Scholarship - ESH International Conference on Lymphomas. Oct 2012.

Newcastle University Graduate School Award - North East Postgraduate Conference 2009.

ESH Scholarship - Biomarkers and Prognosis in Malignant Lymphoma ESH-EHA Scientific Workshop. Apr 2008.

Administrative

COST Action CA17138 EUROGRAFT Management Committee

COST Action CA17138 EUROGRAFT Science Communication Manager

Reviewer for the Newcastle Biobank

RealICM (Researchers Altogether ICM) Committee, Newcastle University

Topic Editor Frontiers Special Edition: Cell to Cell Communication by Extracellular Vesicles

Board Member: Social Media, UK Society for Extracellular Vesicles (UKEV)

Websites

Google Scholar

Loop

ORCID

@RECrossland

Memberships

British Association for Cancer Research (BACR)

European Association for Cancer Research (EACR)

British Society for Haematology (BSH)

Pathological Society

Biochemical Society

UK Society for Extracellular Vesicles (UKEV)

Federation of European Biochemical Societies (FEBS)

European Federation for Immunogenetics (EFI)

My Research

My research focuses on the molecular profiling of autoimmune and inflammatory disorders. I am particularly interested in the role of extracellular vesicles (EVs) and their molecular cargo in disease pathology, as biomarkers for diagnosis and prognosis, and as potential therapeutic agents. I am currently investigating the beneficial effects of mesenchymal stem cell (MSC) derived EVs in chondrocyte regeneration as a potential therapy for osteoarthritis. I am also interested in EV molecular profiles in acute and chronic graft versus host disease, and their biomarkers potential.

Research Goal

To develop/improve acellular approaches as therapeutic strategies for regenerative medicine and controlling inflammation.

Research areas include the role of EVs in:

• Immunomodulation: MSC-EVS, Treg-EVs etc (mechanistic/therapeutic)
• Disease diagnosis and prognosis as potential molecular biomarkers
• Regenerative medicine: MSC-EVs for bone/cartilage regeneration, skin wound healing

Extracellular Vesicles

Extracellular vesicles (EVs) are small particles released by all cells, including bacteria, plants and animals. The vesicles contain essential proteins and genetic information that provide an insight into the health and status of the cells from which they derive. EVs also form a novel way for cells to communicate with each other, by transferring their informative cargo between cells. In this way, EVs can influence neighbouring cells, potentially changing both their behaviour and their genetic information. This, in turn, can affect the function of the cell. 

The study of EVs is at the frontier of basic biology, and these small particles have fundamental implications for both health and disease. EVs can be isolated from many biological fluids, including;

• Blood
• Milk
• Saliva
• Urine
• Cerebrospinal fluid
• Media from culture cells, bacteria and yeast.

BSc

Annual undergraduate students from BSc Biomedical Sciences

MRes

Annual MRes students

Clinical

4^th year elective medical student projects

PhD

Mrs Kay Carruthers (current)

Dr Sadaf Atarod (alumnus)

Dr Rihab Gam (alumnus)

Other Teaching

Versus Arthritis Tissue Engineering Centre Training and Development Programme Coordinator

COST Action CA17138 Short Term Scientific Mission Supervisor

Celleurope Initial Training Network: Immunohistochemistry Workshop and Molecular Biology Workshop.

• Ahmed FW, Bakhashab S, Bastaman IT, Crossland RE, Glanville M, Weaver JU. Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study. International Journal of Molecular Sciences 2018, 19(10), 3242.
• Atarod S, Norden J, Bibby LA, Janin A, Ratajczak P, Lendrem C, Pearce KF, Wang XN, O'Reilly S, Van Laar JM, Collin M, Dickinson AM, Crossland RE. Differential MicroRNA Expression Levels in Cutaneous Acute Graft-versus-Host Disease. Frontiers in Immunology 2018, 9, 1485.
• Juric MK, Shevtsov M, Mozes P, Ogonek J, Crossland RE, Dickinson AM, Greinix HT, Holler E, Weissinger EM, Multhoff G. B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 2017, 7, 660.
• Crossland RE, Norden J, Juric MK, Green K, Pearce KF, Lendrem C, Greinix HT, Dickinson AM. Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease. Frontiers in Immunology 2017, 8, 308.
• Gam R, Shah P, Crossland RE, Norden J, Dickinson AM, Dressel R. Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Frontiers in Immunology 2017, 8, 380.
• Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
• Crossland RE, Norden J, Juric MK, Pearce KF, Lendrem C, Bibby LA, Collin M, Greinix HT, Dickinson AM. Serum and Extracellular Vesicle MicroRNAs miR-423, miR-199, and miR-93* As Biomarkers for Acute Graft-versus-Host Disease. Frontiers in Immunology 2017, 8, 1446.
• Crossland RE, Norden J, Bibby LA, Davis J, Dickinson AM. Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. Journal of Immunological Methods 2016, 429, 39-49.
• Jalapothu D, Boieri M, Crossland RE, Shah P, Butt IA, Norden J, Dressel R, Dickinson AM, Inngjerdingen M. Tissue-specific expression Patterns of Microrna during acute graft-versus-host Disease in the rat. Frontiers in Immunology 2016, 7, 361.
• Atarod S, Pearce K, Norden J, Lendrem C, Crossland R, Wang XN, Sviland L, Janin A, Collin M, Dickinson A. Differential microRNA expressions in cutaneous acute graft-versus-host disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
• Crossland RE, Green K, Bacon C, Rand V. Direct digital profiling of multiplexed mRNA expression from degraded formalin fixed paraffin embedded aggressive paediatric B-cell lymphoma tumour tissue. In: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley.
• Zhou P, Crossland R, Erhorn A, Rand V. High-resolution copy number analysis using low input, degraded DNA from fine-needle aspirates and macrodissected archival Burkitt lymphoma material. In: Fifth International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: British Journal of Haematology.
• Gam R, Norden J, Crossland R, Pearce K, Dickinson AM, Univ Newcastle Upon Tyne. IRAK1 and miR-146a for predicting the outcome of allogeneic haematopoietic stem cell transplantation. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
• Gam R, Norden J, Crossland R, Pearce K, Holler E, Dressel R, Dickinson AM, Framework CellEurope Project, Professor Anne Dickinson Univ Newc. MICA genotype, serum and expression level effects on the outcome of HSCT. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
• Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ. Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. Journal of Molecular Diagnostics 2015, 17(1), 19-30.
• Crossland RE, Norden J, Bibby L, Collin M, Dickinson A. Serum MicroRNAs MiR-146a, MiR-199, MiR-93*and MiR-423 as Biomarkers for Graft Versus Host Disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
• Crossland RE, Norden J, Collin M, Dickinson A. Urinary MicroRNA Expression is Associated with Incidence and Severity of Graft Versus Host Disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
• Crossland RE, Mainou-Fowler T, Sieniawski M, Bacon C, Rand V. High BACH2 gene Expression Is an Indicator of Poor Prognosis in Adult Diffuse Large B-Cell Lymphoma Treated with R-CHOP. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA: American Society of Hematology.
• Rand V, Johnstone S, Crossland RE, Wilkinson S, Hall AG. The Genomic Landscape of Relapsed B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in Adolescents and Adults. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA: American Society of Hematology.
• Crossland RE, Norden J, Collin M, Dickinson AM. Urinary Micrornas MiR-377, MiR-423, MiR-93 and MiR-199 As Biomarkers for Graft Versus Host Disease. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA, USA: American Society of Hematology.
• Crossland RE, Norden J, Bibby L, Davis J, Dickinson AM. Validation of Isolation Methodology and Endogenous Control Selection for qRT-PCR Assessment of Microrna Expression in Serum and Urine Exosomes. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA, USA: American Society of Hematology.
• Culpin RE, Sieniawski M, Proctor SJ, Menon G, Mainou-Fowler T. MicroRNAs are suitable for assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents an appropriate reference microRNA for diffuse large B-cell lymphoma studies. Journal of Clinical Pathology 2013, 66(3), 249-252.
• Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B-cell lymphoma patients. Histopathology 2013, 63(6), 788-801.
• Mazumdar R, Evans P, Culpin R, Bailey J, Allsup D. The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukemia and of survival following first-line chemotherapy. Leukemia Research 2013, 37(6), 614-618.
• Culpin R, Sieniawski M, Anderson J, Angus B, Proctor S, Menon G, McCabe K, Milne P, Crosier S, Mainou-Fowler T. Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
• Culpin R, Pearce K, Bailey J, Pointon J, Sunter N, Bailey J, Evans P, Allsup D, Allan J, Mainou-Fowler T. MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
• Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. International Journal of Oncology 2010, 37(2), 367-376.
• Anderson JJ, Fordham S, Overman L, Dignum H, Wood K, Proctor SJ, Crosier S, Angus B, Culpin RE, Mainou-Fowler T. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. International Journal of Oncology 2009, 35(5), 961-971.